News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
857,873 Results
Type
Article (87225)
Company Profile (722)
Press Release (769901)
Multimedia
Podcasts (163)
Webinars (25)
Section
Business (232969)
Career Advice (4136)
Deals (39781)
Drug Delivery (133)
Drug Development (91201)
Employer Resources (201)
FDA (18245)
Job Trends (17387)
News (397190)
Policy (39894)
Tag
Academia (3003)
Academic (2)
Accelerated approval (17)
Adcomms (33)
Allergies (117)
Alliances (56979)
ALS (135)
Alzheimer's disease (1640)
Antibody-drug conjugate (ADC) (204)
Approvals (18234)
Artificial intelligence (452)
Autoimmune disease (48)
Automation (23)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (146)
Biotechnology (483)
Bladder cancer (118)
Brain cancer (46)
Breast cancer (435)
Cancer (3515)
Cardiovascular disease (306)
Career advice (3550)
Career pathing (36)
CAR-T (228)
CDC (46)
Cell therapy (625)
Cervical cancer (29)
Clinical research (74892)
Collaboration (1271)
Company closure (4)
Compensation (852)
Complete response letters (50)
COVID-19 (2939)
CRISPR (77)
C-suite (493)
Cystic fibrosis (129)
Data (3709)
Decentralized trials (2)
Denatured (58)
Depression (96)
Diabetes (412)
Diagnostics (7042)
Digital health (30)
Diversity (10)
Diversity, equity & inclusion (49)
Drug discovery (214)
Drug pricing (168)
Drug shortages (36)
Duchenne muscular dystrophy (181)
Earnings (98629)
Editorial (52)
Employer branding (25)
Employer resources (169)
Events (132373)
Executive appointments (952)
FDA (20452)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (11)
Funding (1126)
Gene editing (163)
Generative AI (44)
Gene therapy (492)
GLP-1 (987)
Government (5345)
Grass and pollen (7)
Guidances (332)
Healthcare (20934)
HIV (48)
Huntington's disease (33)
IgA nephropathy (52)
Immunology and inflammation (218)
Immuno-oncology (17)
Indications (45)
Infectious disease (3156)
Inflammatory bowel disease (177)
Inflation Reduction Act (13)
Influenza (86)
Intellectual property (158)
Interviews (814)
IPO (17921)
IRA (59)
Job creations (5196)
Job search strategy (2863)
Kidney cancer (15)
Labor market (69)
Layoffs (624)
Leadership (30)
Legal (10144)
Liver cancer (89)
Longevity (12)
Lung cancer (510)
Lymphoma (250)
Machine learning (22)
Management (65)
Manufacturing (553)
MASH (117)
Medical device (14824)
Medtech (14841)
Mergers & acquisitions (22672)
Metabolic disorders (1059)
Multiple sclerosis (116)
NASH (23)
Neurodegenerative disease (181)
Neuropsychiatric disorders (49)
Neuroscience (2526)
NextGen: Class of 2025 (7687)
Non-profit (5095)
Now hiring (54)
Obesity (534)
Opinion (302)
Ovarian cancer (113)
Pain (152)
Pancreatic cancer (145)
Parkinson's disease (213)
Partnered (27)
Patents (380)
Patient recruitment (259)
Peanut (56)
People (66041)
Pharmaceutical (143)
Pharmacy benefit managers (25)
Phase I (23089)
Phase II (32519)
Phase III (24477)
Pipeline (2429)
Policy (277)
Postmarket research (3554)
Preclinical (10425)
Press Release (72)
Prostate cancer (171)
Psychedelics (49)
Radiopharmaceuticals (281)
Rare diseases (594)
Real estate (7411)
Recruiting (76)
Regulatory (27658)
Reports (64)
Research institute (2674)
Resumes & cover letters (650)
Rett syndrome (11)
RNA editing (15)
RSV (64)
Schizophrenia (117)
Series A (183)
Series B (139)
Service/supplier (30)
Sickle cell disease (75)
Special edition (24)
Spinal muscular atrophy (168)
Sponsored (39)
Startups (4314)
State (2)
Stomach cancer (17)
Supply chain (92)
Tariffs (82)
The Weekly (103)
Vaccines (1006)
Venture capital (63)
Weight loss (366)
Women's health (56)
Worklife (21)
Date
Today (3)
Last 7 days (536)
Last 30 days (2242)
Last 365 days (33877)
2025 (23412)
2024 (38139)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1278)
Alabama (78)
Alaska (7)
Arizona (293)
Arkansas (14)
Asia (50778)
Australia (8919)
California (8859)
Canada (2689)
China (829)
Colorado (375)
Connecticut (393)
Delaware (238)
Europe (116613)
Florida (1307)
Georgia (302)
Hawaii (3)
Idaho (67)
Illinois (784)
India (45)
Indiana (427)
Iowa (19)
Japan (266)
Kansas (121)
Kentucky (35)
Louisiana (20)
Maine (75)
Maryland (1209)
Massachusetts (6680)
Michigan (295)
Minnesota (540)
Mississippi (4)
Missouri (113)
Montana (32)
Nebraska (26)
Nevada (101)
New Hampshire (76)
New Jersey (2445)
New Mexico (31)
New York (2414)
North Carolina (1348)
North Dakota (10)
Northern California (3936)
Ohio (279)
Oklahoma (18)
Oregon (49)
Pennsylvania (1849)
Puerto Rico (18)
Rhode Island (44)
South America (1654)
South Carolina (45)
South Dakota (1)
Southern California (3362)
Tennessee (142)
Texas (1384)
United States (32887)
Utah (265)
Virginia (238)
Washington D.C. (82)
Washington State (758)
West Virginia (4)
Wisconsin (91)
There are 857,873 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Obesity
EASD 2025: Orforglipron in Focus, the Case for Cardiovascular Benefits, More
While Eli Lilly’s orforglipron is top of mind heading into the European Association for the Study of Diabetes meeting this week, experts told
BioSpace
the conference will also provide important insights into the therapeutic benefits of incretin therapies beyond weight loss.
September 15, 2025
·
6 min read
·
Tristan Manalac
FDA
FDA Action Alert: Merck, Sanofi, Biogen and More
On the FDA’s docket for the back half of September is Merck’s proposed subcutaneous formulation of its blockbuster cancer drug Keytruda.
September 15, 2025
·
6 min read
·
Tristan Manalac
Immunology and inflammation
Rush of Targeted Myasthenia Gravis Therapies Hit Once Sparse Market
After decades without much movement, a handful of new treatments for this rare autoimmune disease are now approved, and several companies, including argenx and Regeneron, have recently released promising late-stage trial results.
September 15, 2025
·
6 min read
·
Amanda Heidt
Press Releases
Zymewire Releases Midyear 2025 Biopharma Report, Enriched with Executive Commentary from Q2 Earning Calls
September 12, 2025
·
1 min read
Press Releases
L7 Informatics Affirms Architecture, Not Data, is the True Moat for AI in Life Sciences
September 12, 2025
·
1 min read
Layoff Tracker
Merck To Cut 125 Employees as It Ends UK R&D Work
Follow along as
BioSpace
tracks job cuts and restructuring initiatives throughout 2025.
September 12, 2025
·
198 min read
·
BioSpace Editorial Staff
Press Releases
OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit
Clinical data from Phase 1b prostate cancer trial to be released in Q4/25 Additionally, updated 2-year overall survival data from all 40 patients in the Phase 2b clinical trial of OST-HER2 in the prevention of delay of recurrent, fully resected, pulmonary metastatic osteosarcoma to be released on October 10, 2025
September 12, 2025
·
5 min read
Patents
AbbVie Adds Four Years of Exclusivity to Rinvoq Franchise With Generics Settlement
The settlement agreement will extend market exclusivity for AbbVie’s JAK inhibitor in the U.S. until 2037—providing pediatric exclusivity is granted.
September 12, 2025
·
2 min read
·
Tristan Manalac
Autoimmune disease
Intercept Withdraws Embattled Liver Drug from US Market
Ocaliva won accelerated approval for primary biliary cholangitis in 2016, which the FDA refused to upgrade to full approval last year after an advisory committee was unable to verify a favorable risk/benefit profile.
September 12, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Trump Carves Tariff Exemptions for Some Pharma Products
President Donald Trump is considering tariff exemptions for certain “non-patented” pharmaceuticals, though the White House has yet to release specific guidelines.
September 12, 2025
·
2 min read
·
Tristan Manalac
1 of 85,788
Next
